Trial Profile
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes (EQoL-MDS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Myelodysplastic syndromes; Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- Acronyms EQol-MDS
- 15 Jul 2023 Primary endpoint has been met, (Duration of platelet response), as per presented at the 28th Congress of the European Haematology Association
- 15 Jul 2023 Primary endpoint has been met, (platelet response in the first 24 weeks), as per presented at the 28th Congress of the European Haematology Association
- 15 Jun 2023 Results of secondary endpoint the changes in patient-reported outcome measures (PROMs) at 24weeks, presented at the 28th Congress of the European Haematology Association